XENON PHARMACEUTICALS INC's ticker is XENE and the CUSIP is 98420N105. A total of 104 filers reported holding XENON PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 0.17 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $375,760 | -11.3% | 11,000 | 0.0% | 0.14% | -7.2% |
Q2 2023 | $423,500 | +7.6% | 11,000 | 0.0% | 0.15% | -1.3% |
Q1 2023 | $393,690 | -9.2% | 11,000 | 0.0% | 0.15% | -14.4% |
Q4 2022 | $433,730 | +9.3% | 11,000 | 0.0% | 0.18% | +4.0% |
Q3 2022 | $397,000 | +18.5% | 11,000 | 0.0% | 0.17% | +29.1% |
Q2 2022 | $335,000 | -0.3% | 11,000 | 0.0% | 0.13% | +21.8% |
Q1 2022 | $336,000 | -2.3% | 11,000 | 0.0% | 0.11% | +4.8% |
Q4 2021 | $344,000 | +104.8% | 11,000 | 0.0% | 0.10% | +90.9% |
Q3 2021 | $168,000 | -18.0% | 11,000 | 0.0% | 0.06% | -16.7% |
Q2 2021 | $205,000 | +4.1% | 11,000 | 0.0% | 0.07% | -2.9% |
Q1 2021 | $197,000 | +16.6% | 11,000 | 0.0% | 0.07% | +7.9% |
Q4 2020 | $169,000 | +38.5% | 11,000 | 0.0% | 0.06% | +23.5% |
Q3 2020 | $122,000 | -11.6% | 11,000 | 0.0% | 0.05% | -19.0% |
Q2 2020 | $138,000 | +10.4% | 11,000 | 0.0% | 0.06% | -8.7% |
Q1 2020 | $125,000 | -13.2% | 11,000 | 0.0% | 0.07% | +15.0% |
Q4 2019 | $144,000 | +45.5% | 11,000 | 0.0% | 0.06% | +33.3% |
Q3 2019 | $99,000 | – | 11,000 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ally Bridge Group (NY) LLC | 266,961 | $10,277,999 | 12.45% |
COMMODORE CAPITAL LP | 1,845,000 | $71,032,500 | 7.98% |
Altium Capital Management LP | 228,000 | $8,778,000 | 6.64% |
TLS Advisors LLC | 33,756 | $1,300 | 5.58% |
GREAT POINT PARTNERS LLC | 530,000 | $20,405,000 | 3.99% |
DAFNA Capital Management LLC | 280,538 | $10,800,713 | 2.95% |
Paradigm Biocapital Advisors LP | 989,327 | $38,089,090 | 2.94% |
Nan Fung Group Holdings Ltd | 114,380 | $4,403,630 | 2.81% |
Avoro Capital Advisors LLC | 4,900,000 | $188,650,000 | 2.56% |
Ghost Tree Capital, LLC | 185,000 | $7,122,500 | 2.35% |